Valiant Laboratories Ltd

Valiant Laborato Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Valiant Laboratories Ltd

₹ 138 1.60%
26 Jul - close price
valiantlabs.in BSE: 543998 NSE: VALIANTLAB
About

Incorporated in 1980, Valiant Laboratories Limited is a pharmaceutical ingredient manufacturing company in India having focuses on manufacturing Paracetamol.[1]

Key Points

Business Profile[1] The company manufactures a single product, i.e., Paracetamol, which has several applications, like in treatment headache, muscle ache, arthritis, back ache, toothache, cold, and fever. Paracetamol is one of the most commonly taken analgesics worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO).

Website BSE NSE
  • Market Cap ₹ 601 Cr.
  • Current Price ₹ 138
  • High / Low ₹ 227 / 129
  • Stock P/E
  • Book Value ₹ 54.5
  • Dividend Yield 0.00 %
  • ROCE -1.64 %
  • ROE -1.71 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Stock is trading at 2.54 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
87.96 70.77 89.92 51.41 59.55 40.52 30.59
77.28 60.84 81.30 47.59 60.94 46.83 35.12
Operating Profit 10.68 9.93 8.62 3.82 -1.39 -6.31 -4.53
OPM % 12.14% 14.03% 9.59% 7.43% -2.33% -15.57% -14.81%
1.47 0.78 1.72 2.44 2.96 1.78 2.50
Interest 0.17 0.04 0.03 0.02 0.02 0.02 0.02
Depreciation 0.37 0.40 0.44 0.46 0.49 0.49 0.52
Profit before tax 11.61 10.27 9.87 5.78 1.06 -5.04 -2.57
Tax % 25.50% 25.51% 20.67% 26.12% 25.47% -30.75% -51.75%
8.66 7.65 7.83 4.27 0.79 -3.50 -1.24
EPS in Rs 5.32 4.70 2.40 1.31 0.24 -0.81 -0.29
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024
334 182
299 190
Operating Profit 35 -8
OPM % 11% -5%
5 10
Interest 0 0
Depreciation 2 2
Profit before tax 38 -1
Tax % 24% -142%
29 0
EPS in Rs 8.91 0.07
Dividend Payout % 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -45%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -110%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: -2%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024
Equity Capital 33 43
Reserves 68 193
60 77
52 29
Total Liabilities 213 343
48 50
CWIP 1 43
Investments 34 38
130 212
Total Assets 213 343

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024
56 2
-55 -144
-1 152
Net Cash Flow -0 10

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024
Debtor Days 97 92
Inventory Days 17 22
Days Payable 62 56
Cash Conversion Cycle 52 57
Working Capital Days 71 109
ROCE % -2%

Shareholding Pattern

Numbers in percentages

3 Recently
Sep 2023Dec 2023Mar 2024Jun 2024
74.94% 74.94% 74.94% 74.94%
8.64% 7.08% 3.48% 1.89%
1.76% 0.43% 0.00% 0.00%
14.66% 17.54% 21.58% 23.18%
No. of Shareholders 37,43415,82114,91414,249

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings